The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges.
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports.
The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it.
Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis.
A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains.
By facilitating public access to the work being done, universities face the challenge of maintaining a balance between being transparent and commercialising IP. LSIPR spoke to the head of the University of Manchester IP about walking the fine line.
The UK Intellectual Property Enterprise Court offers a quick and cheap way to resolve IP disputes, but very few have involved life sciences inventions. Mark Didmon and Simon Curtis of Potter Clarkson ask whether IPEC is an appropriate forum for handling these types of patent disputes.
The EPO’s Enlarged Board of Appeal is about to deliver its long-awaited final decision on the patentability of plants, in the hope that it will at least bring legal certainty to patentees and unfreeze pending appeals. Franz-Josef Zimmer and Markus Grammel of Grünecker report.
A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports.